Allergan's modified abicipar pegol decreases intraocular inflammation

Ahead of a BLA submission to FDA this half for AMD therapy abicipar pegol, Allergan and Molecular Partners reported top-line safety data from the Phase II MAPLE trial showing that an optimized formulation of the product led to a lower incidence of intraocular inflammation compared with the rate observed in prior Phase III trials.

Among MAPLE's 123 patients with neovascular age-related macular degeneration who received abicipar produced using a modified manufacturing process, the incidence of intraocular inflammation was 8.9%. Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said most of the events were assessed as mild to moderate in severity. The incidence of severe intraocular inflammation was 1.6%...